# Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

> **NCT01401257** · PHASE2 · COMPLETED · sponsor: **Pharnext S.C.A.** · enrollment: 80 (actual)

## Conditions studied

- Charcot-Marie-Tooth Disease
- Hereditary Neuropathy With Liability to Pressure Palsies
- Genetic Disorders

## Interventions

- **DRUG:** PXT3003 Low dose
- **DRUG:** PXT3003 Intermediate Dose
- **DRUG:** PXT3003 High Dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01401257
- **Lead sponsor:** Pharnext S.C.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-10
- **Final completion:** 2012-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01401257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01401257, "Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01401257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*